［1］Liu N，Sheng X，Liu Y，et al.Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas［J］.Oncotargets & Therapy，2013，6(6)：615-619.
［2］Wu Yuan.Advances in research on the role of CD70 in anti-tumor therapy［J］.Tumor，2013，33(2)：197-201.［吴瑗.CD70在肿瘤治疗中的研究进展［J］.肿瘤，2013，33(2)：197-201.］
［3］Ruf M，Moch H，Schraml P.Interaction of tumor cells with infiltrating lymphocytes via CD70 and CD27 in clear cell renal cell carcinoma［J］.Oncoimmunology，2015，4(12)：e1049805.
［4］Nolte MA，Van ORW，Van GKPJM，et al.Timing and tuning of CD27-CD70 interactions：The impact of signal strength in setting the balance between adaptive responses and immunopathology［J］.Immunological Reviews，2009，229(1)：216-231.
［5］Camerini D，Walz G，Loenen WA，et al.The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family［J］.Journal of Immunology，1991，147(9)：3165-3169.
［6］Hashimotookada M，Kitawaki T，Kadowaki N，et al.The CD70-CD27 interaction during the stimulation with dendritic cells promotes naive CD4(+) T cells to develop into T cells producing a broad array of immunostimulatory cytokines in humans［J］.International Immunology，2009，21(8)：891-904.
［7］Manocha M，Rietdijk S，Laouar A，et al.Blocking CD27-CD70 costimulatory pathway suppresses experimentalcolitis［J］.Journal of Immunology，2009，183(1)：270-276.
［8］Chen P，Nogusa S，Thapa RJ，et al.Anti-CD70 immunocytokines for exploitation of interferon-induced RIP1-dependent necrosis in renal cell carcinoma［J］.Plos One，2013，8(4)：e61446.
［9］Tang CY，Ge HT，Lin ZG，et al.Potential role of runaway CD70 in the occurrence and treatment of glioma［J］.Progress in Modern Biomedicine，2016，16(7)：1363-1365.［唐重阳，葛海涛，林志国，等.失控的CD70在脑胶质瘤的发生与治疗中的潜在作用［J］.现代生物医学进展,2016，16(7)：1363-1365.］
［10］De Meulenaere A，Vermassen T.CD70 expression and its correlation with clinicopathological variables in squamous cell carcinoma of thehead and neck［J］.Pathobiology，2016，83(6)：327-333.
［11］Yang ZZ，Novak AJ，Ziesmer SC，et al.CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells［J］.Blood，2007，110(7)：2537-2544.
［12］Nilsson A，Milito AD，Mowafi F，et al.Expression of CD27-CD70 on early B cell progenitors in the bone marrow：Implication for diagnosis and therapy of childhood ALL［J］.Experimental Hematology，2005，33(12)：1500-1507.
［13］Kaufmann Y，Amariglio N，Rosenthal E，et al.Proliferation response of leukemic cells to CD70 ligation oscillates with recurrent remission and relapse in a low-grade lymphoma［J］.Journal of Immunology，2005，175(10)：6940-6947.
［14］Israel E，Kapelushnik J，Yermiahu T，et al.Expression of CD24 on CD19-CD79a+ early B-cell progenitors in human bone marrow［J］.Cellular Immunology，2005，236(1-2)：171-178.
［15］Steffen Aulwurm，Wischhusen J，Friese M，et al.Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo［J］.International Journal of Cancer，2006，118(7)：1728-1735.
［16］Soukup K，Wang X.Radiation meets immunotherapy-a perfect match in the era of combination therapy［J］?International Journal of Radiation Biology，2015，91(4)：1-15.
［17］Mcearchern JA，Smith LM，Mcdonagh CF，et al.Preclinical characterization of SGN-70，a humanized antibody directed against CD70［J］.Clinical Cancer Research，2009，14(23)：7763-7772.
［18］Wu H，Han ZL，Cao YL，et al.The expression of CD70 in hepatocellular carcinoma and its suppressive impact on proliferation of lymphocytes［J］.Journal of Shandong University(Health Sciences)，2008，46(01)：27-30.［吴晗，韩振龙，曹英林，等.CD70在肝癌中的表达及其对淋巴细胞增殖抑制作用的研究［J］.山东大学学报(医学版)，2008，46(01)：27-30.］
［19］Allard B，Pommey S，Smyth MJ，et al.Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs［J］.Clinical Cancer Research，2013，19(20)：5626-5635.
［20］Claus C，Riether C，Schürch C，et al.CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth［J］.Cancer Research，2012，72(14)：603.
［21］Jacobs J，Zwaenepoel K，Rolfo C，et al.Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer［J］.Oncotarget，2015，6(15)：13462-13475.
［22］Silence K，Dreier T，Moshir M，et al.ARGX-110，a highly potent antibody targeting CD70，eliminates tumors via both enhanced ADCC and immune checkpoint blockade［J］.Mabs，2014，6(2)：523-532.
［23］Boursalian TE，Mcearchern JA，Law CL，et al.Targeting CD70 for human therapeutic use［J］.Advances in Experimental Medicine & Biology，2009，647(647)：108-119.
［24］Jacobs J，Deschoolmeester V，Zwaenepoel K，et al.CD70：An emerging target in cancer immunotherapy［J］.Pharmacology & Therapeutics，2015，155：1-10.
［25］Yoshimoto Y，Suzuki Y，Mimura K，et al.Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model［J］.Plos One，2014，9(3)：e92572.
［26］Tannir NM，Forero-Torres A.Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma［J］.Investigational New Drugs，2014，32(6)：1246-1257.
［27］Sandall S，Anderson M，Jonas M，et al.Abstract 2647：SGN-CD70A，a novel and highly potent anti-CD70 ADC，induces double-strand DNA breaks and is active in models of MDR+ renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL)［J］.Cancer Research，2014，74(19 Supplement)：2647.
［28］Jumbe NL，Fanslow W，Patel S，et al.Abstract 3359：Translating preclinical PK/PD tumor volume modeling data to predict AMG172 PK and dose-escalation scheme in FIH［J］.Cancer Research，2013，73(8 Suppl)：3359.
［29］Awada A，Rolfo C，Rottey S，et al.(2014).A Phase I，first-in-human study of ARGX-110，a monoclonal antibody targeting CD70，a receptor involved in immune escape and tumor growth in solid and hematologic malignancies.Presented at ASCO Annual Meeting［J］.J Clin Oncol，2014，32(5s）：abstr 3023.
［30］Wensveen FM，Unger PP，Kragten NA，et al.CD70-driven costimulation induces survival or Fas-mediated apoptosis of T cells depending on antigenic load［J］.Journal of Immunology，2012，188(9)：4256-4267.
［31］Abolhassani H，Edwards ES，Ikinciogullari A，et al.Combined immunodeficiency and epstein-barr virus-induced B cell malignancy in humans with inherited CD70 deficiency［J］.The Journal of Experimental Medicine，2016，2016：0849.